HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

lesofavumab

a human monoclonal immunoglobulin G1 (IgG1) antibody that binds to a highly conserved region of the hemagglutinin protein of influenza B virus

Also Known As:

MHAB5553A; RG70026; RO7045557

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Burleson, Stefanie C M: 1 article (01/2019)
2.	Halpern, Wendy G: 1 article (01/2019)
3.	Laing, Steven T: 1 article (01/2019)
4.	McBride, Jacqueline M: 1 article (01/2019)
5.	Nguyen, Allen: 1 article (01/2019)
6.	Prell, Rodney A: 1 article (01/2019)
7.	Rao, Gautham K: 1 article (01/2019)
8.	Sheinson, Daniel: 1 article (01/2019)
9.	Zhang, Crystal: 1 article (01/2019)
10.	Anderson, Malia: 1 article (01/2017)

Related Diseases

1.	Human Influenza (Influenza) 01/01/2019 - "In these studies, the high dose of 15 mg/kg MHAB5553A resulted in substantial attenuation of influenza pneumonia, with more modest effects at 1.5 mg/kg; whereas MHAB5553A treatment at 0.15 or 0.015 mg/kg was generally comparable to vehicle-treated controls. " 01/01/2019 - "These studies were conducted to investigate the potential of MHAB5553A, a broadly specific, neutralizing therapeutic anti-influenza B antibody, to elicit ADE of infection and disease in mouse models of influenza B infection. " 01/01/2019 - "Our results demonstrate that MHAB5553A across a broad range of doses did not enhance primary influenza B infection or disease in this model, and represent a nonclinical de-risking of the ADE potential with this antibody." 01/01/2017 - "MHAB5553A, a human monoclonal immunoglobulin G1 (IgG1) antibody that binds to a highly conserved region of the hemagglutinin protein of influenza B virus, is being examined as a novel therapeutic for the treatment of influenza B patients with severe disease. "
2.	Pneumonia (Pneumonitis) 01/01/2019 - "In these studies, the high dose of 15 mg/kg MHAB5553A resulted in substantial attenuation of influenza pneumonia, with more modest effects at 1.5 mg/kg; whereas MHAB5553A treatment at 0.15 or 0.015 mg/kg was generally comparable to vehicle-treated controls. "
3.	Infections 01/01/2019 - "These studies were conducted to investigate the potential of MHAB5553A, a broadly specific, neutralizing therapeutic anti-influenza B antibody, to elicit ADE of infection and disease in mouse models of influenza B infection. " 01/01/2019 - "Our results demonstrate that MHAB5553A across a broad range of doses did not enhance primary influenza B infection or disease in this model, and represent a nonclinical de-risking of the ADE potential with this antibody."

Related Drugs and Biologics

1.	Proteins (Proteins, Gene)
2.	Immunoglobulins (Immunoglobulin)
3.	Immunoglobulin G (IgG)
4.	Hemagglutinins (Hemagglutinin)